PDF(Sci-hub)
Abstract：
Administration of the diuretic and NKCC1 chloride cotransporter antagonist bumetanide reduces the severity of autism spectrum disorders in children, and this effect is mediated by a reduction of the elevated intracellular chloride concentrations and a reinforcement of GABAergic inhibition (Lemonnier et al Transl Psychiatry. 2012;2:e202; Tyzio et al Science. 2014;343:675-679). Here, we report that this treatment also reduces the severity of symptoms in an adolescent with schizophrenia. Long-term treatment reduced hallucinations significantly, suggesting that this treatment may also be useful to treat schizophrenia. Further clinical trials and experimental studies are warranted to test this hypothesis.
摘要：
利尿剂和NKCC1氯化物协同转运蛋白拮抗剂布美他尼的给药可降低儿童自闭症谱系障碍的严重程度，这种作用是通过降低细胞内氯化物浓度和增强GABA能抑制来介导的（Lemonnier等人TranslPsychiatry。2012；2：e202；Tyzio等人的科学。2014；343：675-679）。这里,我们报告说，这种治疗还可以减轻青少年精神分裂症患者的症状严重程度。长期治疗显著减少幻觉，这表明这种治疗也可能对治疗精神分裂症有用。需要进一步的临床试验和实验研究来检验这一假设。
